Arsenic trioxide is a chemotherapeutic agent of the idiopathic function used to treat leukemia that is unresponsive to first-line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Arsenic is a nonessential trace element that is widely distributed in nature. Arsenic was used in medicinal agents in the 19th and early 20th centuries, but has been replaced by safer and more effective agents and has not been in use for over 50 years. Nevertheless, arsenic is found widely in nature and accidental or intentional acute or chronic exposures to moderate or high levels of arsenic can cause liver injury, sometimes presenting long after the exposure.
Arsenic is a naturally occurring allotropic pnictogen and metalloid trace element with atomic symbol As, atomic number 33, and atomic weight 74.92 that is found in water, air, food, and soil, and has a role as a micronutrient. Arsenic, which is highly toxic with acute or chronic exposure to moderate or high levels through an unknown mechanism of action, is used in many industrial processes, as well as in pharmaceuticals, feed additives, and pesticides. It is characterized as a white, yellow, gray metallic, or black solid that is odorless. Exposure occurs by inhalation, ingestion, or contact.
Arsenic is a naturally occurring element widely distributed in the earth’s crust. In the environment, arsenic is combined with oxygen, chlorine, and sulfur to form inorganic arsenic compounds. Arsenic in animals and plants combines with carbon and hydrogen to form organic arsenic compounds. Inorganic arsenic compounds are mainly used to preserve the wood. Copper chromate arsenic (CCA) is used to make “pressure-treated” lumber. CCA is no longer used in the U.S. for residential uses; it is still used in industrial applications. Organic arsenic compounds are used as pesticides, primarily on cotton plants.
Mechanism of Action
Inorganic arsenicals affect the bone marrow & alter the cellular composition of the blood. The vascularity of the bone marrow is inserted. Moderate doses of arsenic lower the erythrocyte count, & large doses cause morphological changes with the appearance of megalocytes & microcytes. Inorganic arsenicals also suppress the production of leukocytes.
The mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis.
Indications
- For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Trisenox is indicated for induction of remission, and consolidation in adult patients with newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, ≤ 10 x 103/µl) in combination with all‑trans‑retinoic acid (ATRA)Relapsed/refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterized by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. The response rate of other acute myelogenous leukemia subtypes to arsenic trioxide has not been examined.
- Arsenic trioxide Mylan is indicated for induction of remission, and consolidation in adult patients with newly diagnosed low to intermediate-risk acute promyelocytic leukemia (APL) (white blood cell count, ≤ 10 x 103/μl) in combination with all-trans-retinoic acid (ATRA)- Relapsed/refractory acute promyelocytic leukemia (APL) (Previous treatment should have included a retinoid and chemotherapy) characterized by the presence of the t(15;17) translocation and/or the presence of promyelocytic leukemia/retinoic acid receptor alpha (PML/RAR alpha) gene. The response rate of other acute myelogenous leukemia subtypes to arsenic trioxide has not been examined.
- Acute Promyelocytic Leukemia (APL)
- Refractory Acute Promyelocytic Leukemia
- Relapsed Acute Promyelocytic Leukemia
Use in Cancer
Arsenic trioxide is approved to be used with tretinoin to treat:
- Acute promyelocytic leukemia (APL) in patients whose cancer has a certain type of chromosome mutation that affects the PML gene and RARA gene. It is used:
- In adults with newly diagnosed APL that is low risk.
- In patients whose cancer has not gotten better or has relapsed after retinoid and anthracycline chemotherapy.
Arsenic trioxide is also being studied in the treatment of other types of cancer.
Contraindications
The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:
- deficiency in thiamine or vitamin B1
- low amount of magnesium in the blood
- high levels of potassium in the blood
- low amount of potassium in the blood
- complete heart block
- torsades de pointes, a type of abnormal heart rhythm
- prolonged QT interval on EKG
- chronic heart failure
- abnormal EKG with QT changes from birth
- pregnancy
- a patient who is producing milk and breastfeeding
- differentiation syndrome in acute promyelocytic leukemia
- chronic kidney disease stage 4 (severe)
- chronic kidney disease stage 5 (failure)
- kidney disease with likely reduction in kidney function
- Child-Pugh class C liver impairment
Dosage
Strengths: 2 mg/mL; 1 mg/mL
Acute Promyelocytic Leukemia
- INDUCTION CYCLE: 0.15 mg/kg IV over 1 to 2 hours once a day until bone marrow remission or up to a maximum of 60 days
CONSOLIDATION CYCLE: 0.15 mg/kg IV over 1 to 2 hours once a day for 25 doses over a period of up to 5 weeks; begin consolidation 3 to 6 weeks after completion of induction therapy
Acute Promyelocytic Leukemia
4 YEARS AND OLDER:
- INDUCTION CYCLE: 0.15 mg/kg IV over 1 to 2 hours once a day until bone marrow remission or up to a maximum of 60 days
CONSOLIDATION CYCLE: 0.15 mg/kg IV over 1 to 2 hours once a day for 25 doses over a period of up to 5 weeks; begin consolidation 3 to 6 weeks after completion of induction therapy - CrCl less than 30 mL/min: Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.
Dose Adjustments
RECOMMENDED DOSE REDUCTION SCHEDULE:
- Starting dose: 0.15 mg/kg IV once daily
- First dose reduction: 0.11 mg/kg IV once daily
- Second dose reduction: 0.1 mg/kg IV once daily
- Third dose reduction: 0.075 mg/kg IV once daily
DOSE ADJUSTMENTS FOR ADVERSE REACTIONS:
DIFFERENTIATION SYNDROME (defined by the presence of 2 or more of the following: unexplained fever, dyspnea, pleural and/or pericardial effusion, pulmonary infiltrates, renal failure, hypotension, weight gain greater than 5 kg):
- Temporarily withhold this drug; treat with dexamethasone 10 mg IV every 12 hours until resolution for a minimum of 3 days.
- Resume this drug when the condition improves and reduce the dose of the withheld drug(s) by 50%.
- Increase the dose of the withheld drug(s) to the recommended dosage after 7 days in the absence of recurrence of symptoms of differentiation syndrome.
- If symptoms reappear, decrease the dose of this drug to the previous dose.
QTC PROLONGATION GREATER THAN 450 MSEC FOR MEN OR GREATER THAN 460 MSEC FOR WOMEN:
- Withhold this drug and any medication known to prolong the QTc interval.
- Replete electrolytes.
- After the QTc normalizes, resume this drug at a 50% reduced dose (0.075 mg/kg once daily) for 7 days.
- If the 50% reduced dose is tolerated for 7 days (in the absence of QTc prolongation), increase the dose of arsenic trioxide injection to 0.11 mg/kg once daily for 7 days.
- Increase the dose of this drug to 0.15 mg/kg in the absence of QTc prolongation during the 14-day dose-escalation period.
HEPATOTOXICITY, DEFINED BY 1 OR MORE OF THE FOLLOWING (total bilirubin [TB] greater than 3 times the upper limit of normal [ULN]; aspartate aminotransferase [AST] greater than 5 x ULN; alkaline phosphatase [AP] greater than 5 x ULN):
- Withhold therapy.
- Resume therapy at a 50% reduced dose of the withheld drug(s) when TB is less than 1.5 x ULN and AP/AST are less than 3 x ULN.
- Increase the dose of the withheld drug(s) back to the recommended dose after 7 days on the reduced dose in the absence of worsening hepatotoxicity.
- Discontinue the withheld drug(s) permanently if hepatotoxicity recurs.
MODERATE (GRADE 2) NONHEMATOLOGIC REACTIONS:
- Temporarily withhold this drug.
- When the adverse reaction resolves to no more than mild (Grade 1), resume this drug reduced by 2 dose levels.
LEUKOCYTOSIS (WBC COUNT GREATER THAN 10 Gi/L):
- Administer hydroxyurea.
- Hydroxyurea may be discontinued when the WBC declines below 10 Gi/L.
MYELOSUPPRESSION, DEFINED BY 1 OR MORE OF THE FOLLOWING (absolute neutrophil count less than 1 Gi/L; platelets less than 50 Gi/L lasting more than 5 weeks):
Consider reducing the dose of arsenic trioxide injection by 1 dose level (see Table 3 below).
- If myelosuppression lasts 50 days or longer OR occurs on 2 consecutive cycles, assess a marrow aspirate for remission status.
- In the case of molecular remission, resume this drug at 1 dose level lower.
Side Effects
The Most Common
- extreme thirst
- frequent urination
- extreme hunger
- weakness
- blurred vision
- dry mouth
- nausea and vomiting
- shortness of breath
- breath that smells fruity
- decreased consciousness
- excessive tiredness
- dizziness
- headache
- diarrhea
- swelling of the arms, hands, feet, ankles, or lower legs
- rash
- itching
- unusual bruising or bleeding
- vomit that is bloody or that looks like coffee grounds
- stool that is black and tarry or contains bright red blood
- decreased urination
- hives
More Common
- abdominal pain
- constipation
- decreased appetite
- diarrhea
- headache
- heartburn
- low heart rate
- nausea
- rash
- symptoms of neuropathy (e.g., numbness, prickling or tingling, burning, freezing, throbbing and/or shooting pain in the hands and or feet)
- tiredness
- trouble swallowing
- vomiting
- weight loss
Rare
- chest pain
- heart rhythm abnormality (e.g., dizziness, fainting, or chest discomfort)
- low blood pressure
- pain in the back, arms, legs, hands, or feet
- pounding heartbeat
- severe nausea, vomiting, diarrhea, or dehydration
- signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
- signs of dehydration (e.g., decreased urine, dry skin, dry and sticky mouth, sleepiness, dizziness, headache, thirst, confusion)
- slow heart rate
- symptoms of high blood sugar (e.g., frequent urination, hunger, thirst)
- symptoms of kidney problems (e.g., pain in the back or side, blood in the urine, nausea, vomiting, fatigue)
- symptoms of liver problems (e.g., feeling more tired than usual, decreased appetite, yellowing of the skin or whites of the eyes, stomach pain, dark urine, nausea, vomiting, itching, or bleeding or bruising more easily than normal)
- symptoms of low levels of phosphate in the blood (e.g., muscle pain and weakness, change in mental state)
- symptoms of lung infection or inflammation (e.g., difficulty breathing, cough, or fever)
- vision changes (e.g., blurred vision, flashes of light, double vision)
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abacavir | Abacavir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Abatacept | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Abatacept. |
| Abciximab | The risk or severity of bleeding can be increased when Abciximab is combined with Arsenic trioxide. |
| Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Arsenic trioxide. |
| Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Arsenic trioxide. |
| Acebutolol | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Acebutolol. |
| Aceclofenac | Aceclofenac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Acemetacin | Acemetacin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Acenocoumarol is combined with Arsenic trioxide. |
| Acetaminophen | Acetaminophen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Acetazolamide | Acetazolamide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Arsenic trioxide. |
| Acetyldigitoxin | Acetyldigitoxin may decrease the cardiotoxic activities of Arsenic trioxide. |
| Acetylsalicylic acid | The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Arsenic trioxide. |
| Aclidinium | Arsenic trioxide may decrease the excretion rate of Aclidinium which could result in a higher serum level. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Arsenic trioxide. |
| Acyclovir | Acyclovir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Arsenic trioxide. |
| Adefovir dipivoxil | Adefovir dipivoxil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Arsenic trioxide. |
| Adenovirus type 7 | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Arsenic trioxide. |
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Arsenic trioxide. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Arsenic trioxide. |
| Albiglutide | The therapeutic efficacy of Albiglutide can be decreased when used in combination with Arsenic trioxide. |
| Albutrepenonacog alfa | Arsenic trioxide may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. |
| Alclofenac | Alclofenac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Arsenic trioxide. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Arsenic trioxide. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Arsenic trioxide. |
| Alfuzosin | The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Arsenic trioxide. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Arsenic trioxide. |
| Aliskiren | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Aliskiren. |
| Allogeneic processed | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Arsenic trioxide. |
| Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Arsenic trioxide. |
| Almasilate | Arsenic trioxide may decrease the excretion rate of Almasilate which could result in a higher serum level. |
| Almotriptan | Almotriptan may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Arsenic trioxide. |
| Alprazolam | Alprazolam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Alteplase | The risk or severity of bleeding can be increased when Alteplase is combined with Arsenic trioxide. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Arsenic trioxide. |
| Amantadine | The risk or severity of QTc prolongation can be increased when Amantadine is combined with Arsenic trioxide. |
| Ambrisentan | The serum concentration of Ambrisentan can be increased when it is combined with Arsenic trioxide. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Arsenic trioxide. |
| Amifostine | The risk or severity of adverse effects can be increased when Amifostine is combined with Arsenic trioxide. |
| Amikacin | Arsenic trioxide may decrease the excretion rate of Amikacin which could result in a higher serum level. |
| Amiloride | Amiloride may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Aminophenazone | Aminophenazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Amiodarone | The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Arsenic trioxide. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Arsenic trioxide. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Arsenic trioxide. |
| Amlodipine | The risk or severity of adverse effects can be increased when Amlodipine is combined with Arsenic trioxide. |
| Ammonium chloride | Arsenic trioxide may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. |
| Amobarbital | Amobarbital may increase the hypotensive activities of Arsenic trioxide. |
| Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Arsenic trioxide. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Arsenic trioxide. |
| Amoxicillin | Amoxicillin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Amphetamine | Amphetamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Amphotericin B | The risk or severity of adverse effects can be increased when Amphotericin B is combined with Arsenic trioxide. |
| Ampicillin | Ampicillin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Amrinone | Arsenic trioxide may decrease the excretion rate of Amrinone which could result in a higher serum level. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Arsenic trioxide. |
| Amyl Nitrite | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Amyl Nitrite. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Arsenic trioxide. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Arsenic trioxide. |
| Anastrozole | The risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Anastrozole. |
| Ancestim | Arsenic trioxide may decrease the excretion rate of Ancestim which could result in a higher serum level. |
| Ancrod | The risk or severity of bleeding can be increased when Ancrod is combined with Arsenic trioxide. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Anifrolumab. |
| Anistreplase | The risk or severity of bleeding can be increased when Anistreplase is combined with Arsenic trioxide. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Antazoline is combined with Arsenic trioxide. |
| Anthrax immune globulin human | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Arsenic trioxide. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Arsenic trioxide. |
| Antihemophilic factor | Arsenic trioxide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Antilymphocyte immunoglobulin (horse). |
| Antipyrine | Antipyrine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Arsenic trioxide. |
| Antithrombin III human | Arsenic trioxide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. |
| Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Arsenic trioxide. |
| Antrafenine | Antrafenine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Apalutamide | Arsenic trioxide may decrease the excretion rate of Apalutamide which could result in a higher serum level. |
| Apixaban | The serum concentration of Apixaban can be increased when it is combined with Arsenic trioxide. |
| Apomorphine | The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Arsenic trioxide. |
| Apremilast | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Apremilast. |
| Ardeparin | The risk or severity of bleeding can be increased when Ardeparin is combined with Arsenic trioxide. |
| Arformoterol | The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Arsenic trioxide. |
| Argatroban | The risk or severity of bleeding can be increased when Argatroban is combined with Arsenic trioxide. |
| Aripiprazole | The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Arsenic trioxide. |
| Aripiprazole lauroxil | The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Arsenic trioxide. |
| Artemether | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Artemether. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Articaine. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Asenapine. |
| Astemizole | The risk or severity of QTc prolongation can be increased when Astemizole is combined with Arsenic trioxide. |
| AstraZeneca COVID-19 Vaccine | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Arsenic trioxide. |
| Atazanavir | The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Arsenic trioxide. |
| Atenolol | The risk or severity of adverse effects can be increased when Atenolol is combined with Arsenic trioxide. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Arsenic trioxide. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Arsenic trioxide. |
| Auranofin | Auranofin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Aurothioglucose | Arsenic trioxide may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Arsenic trioxide. |
| Axitinib | The serum concentration of Axitinib can be increased when it is combined with Arsenic trioxide. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Arsenic trioxide. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Arsenic trioxide. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Arsenic trioxide. |
| Azelaic acid | Azelaic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Azilsartan medoxomil | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Azilsartan medoxomil. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Arsenic trioxide. |
| Aztreonam | Aztreonam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Bacillus calmett | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Arsenic trioxide. |
| Bacillus calmette- | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Arsenic trioxide. |
| Bacillus calmette- | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Arsenic trioxide. |
| Bacitracin | Bacitracin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Baclofen | Baclofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Balsalazide | Balsalazide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Baricitinib | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Arsenic trioxide. |
| BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Arsenic trioxide. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Arsenic trioxide. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Arsenic trioxide. |
| Belantamaba | The serum concentration of Belantamab mafodotin can be increased when it is combined with Arsenic trioxide. |
| Belatacept | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belinostat. |
| Belumosudil | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belumosudil. |
| Bemiparin | The risk or severity of bleeding can be increased when Bemiparin is combined with Arsenic trioxide. |
| Benazepril | The risk or severity of adverse effects can be increased when Benazepril is combined with Arsenic trioxide. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Arsenic trioxide. |
| Bendroflumethiazide | Bendroflumethiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Benorilate | Benorilate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Benoxaprofen | Benoxaprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Benserazide | Arsenic trioxide may decrease the excretion rate of Benserazide which could result in a higher serum level. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Arsenic trioxide. |
| Benznidazole | Arsenic trioxide may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Benzocaine. |
| Benzthiazide | Benzthiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Benzydamine | Benzydamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Benzyl alcohol. |
| Bepotastine | Arsenic trioxide may decrease the excretion rate of Bepotastine which could result in a higher serum level. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Bepridil. |
| Berotralstat | The serum concentration of Berotralstat can be increased when it is combined with Arsenic trioxide. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Arsenic trioxide. |
| Betaxolol | The risk or severity of adverse effects can be increased when Betaxolol is combined with Arsenic trioxide. |
| Bethanidine | Arsenic trioxide may increase the hypotensive activities of Bethanidine. |
| Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Arsenic trioxide. |
| Bevacizumab | The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Arsenic trioxide. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Arsenic trioxide. |
| Bicisate | Arsenic trioxide may decrease the excretion rate of Bicisate which could result in a higher serum level. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Arsenic trioxide. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bimekizumab. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Arsenic trioxide. |
| Bismuth subgallate | Arsenic trioxide may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. |
| Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Arsenic trioxide. |
| Bisoxatin | Arsenic trioxide may decrease the excretion rate of Bisoxatin which could result in a higher serum level. |
| Bivalirudin | The risk or severity of bleeding can be increased when Bivalirudin is combined with Arsenic trioxide. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Arsenic trioxide. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Blinatumomab. |
| Bordetella pertussis | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Arsenic trioxide. |
| Bortezomib | The serum concentration of Bortezomib can be increased when it is combined with Arsenic trioxide. |
| Bosentan | Arsenic trioxide may increase the hypotensive activities of Bosentan. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Arsenic trioxide. |
| Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Arsenic trioxide. |
| Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Arsenic trioxide. |
| Brivaracetam | Arsenic trioxide may decrease the excretion rate of Brivaracetam which could result in a higher serum level. |
| Brodalumab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Brodalumab. |
| Bromazepam | Arsenic trioxide may decrease the excretion rate of Bromazepam which could result in a higher serum level. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Arsenic trioxide. |
| Bromotheophylline | Bromotheophylline may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Arsenic trioxide. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Arsenic trioxide. |
| Budesonide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Budesonide. |
| Bumadizone | Bumadizone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Bumetanide | Bumetanide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Bupivacaine. |
| Bupropion | Bupropion may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Arsenic trioxide. |
| Buspirone | Buspirone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Arsenic trioxide. |
| Butabarbital | Butabarbital may increase the hypotensive activities of Arsenic trioxide. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Butacaine. |
| Butalbital | Butalbital may increase the hypotensive activities of Arsenic trioxide. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Butamben. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Arsenic trioxide. |
| Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Arsenic trioxide. |
| Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Arsenic trioxide. |
| Canagliflozin | The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide. |
| Canakinumab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Canakinumab. |
| Candesartan cilexetil | The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Arsenic trioxide. |
| Cangrelor | The risk or severity of bleeding can be increased when Cangrelor is combined with Arsenic trioxide. |
| Canrenoic acid | Canrenoic acid may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Arsenic trioxide. |
| Caplacizumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Arsenic trioxide. |
| Capreomycin | Arsenic trioxide may decrease the excretion rate of Capreomycin which could result in a higher serum level. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Capsaicin. |
| Captopril | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Captopril. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Arsenic trioxide. |
| Carbetocin | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Carbetocin. |
| Carbidopa | Carbidopa may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Arsenic trioxide. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Arsenic trioxide. |
| Carfilzomib | The serum concentration of Carfilzomib can be increased when it is combined with Arsenic trioxide. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Arsenic trioxide. |
| Carprofen | Carprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Carvedilol | The risk or severity of adverse effects can be increased when Carvedilol is combined with Arsenic trioxide. |
| Cefaclor | Cefaclor may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefadroxil | Cefadroxil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefalotin | Cefalotin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefamandole | Cefamandole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefapirin | Cefapirin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefazolin | Cefazolin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefdinir | Cefdinir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefditoren | Cefditoren may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefepime | Cefepime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefmenoxime | Cefmenoxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefmetazole | Cefmetazole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefonicid | Cefonicid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefoperazone | Cefoperazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Ceforanide | Ceforanide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefotaxime | Cefotaxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefotetan | Cefotetan may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefotiam | Cefotiam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefoxitin | Cefoxitin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefpiramide | Cefpiramide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefpirome | Cefpirome may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefpodoxime | Cefpodoxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefprozil | Cefprozil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefradine | Cefradine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Ceftaroline fosamil | Ceftaroline fosamil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Ceftazidime | Ceftazidime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Ceftibuten | Ceftibuten may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Ceftizoxime | Ceftizoxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Ceftobiprole | Ceftobiprole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Ceftolozane | Arsenic trioxide may decrease the excretion rate of Ceftolozane which could result in a higher serum level. |
| Ceftriaxone | Ceftriaxone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cefuroxime | Cefuroxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Celecoxib | Celecoxib may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Arsenic trioxide. |
| Cephalexin | Cephalexin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cephaloglycin | Cephaloglycin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with Arsenic trioxide. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Arsenic trioxide. |
| Cevimeline | Cevimeline may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Chloral hydrate | Arsenic trioxide may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Arsenic trioxide. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Arsenic trioxide. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Arsenic trioxide. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Chloroprocaine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Arsenic trioxide. |
| Chlorothiazide | Chlorothiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Chloroxylenol | Arsenic trioxide may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Arsenic trioxide. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Arsenic trioxide. |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Arsenic trioxide. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Arsenic trioxide. |
| Chlorthalidone | Chlorthalidone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Chlorzoxazone | Chlorzoxazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Choline C 11 | Arsenic trioxide may decrease the excretion rate of Choline C 11 which could result in a higher serum level. |
| Choline magnesium trisalicylate | Choline magnesium trisalicylate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Choline salicylate | Arsenic trioxide may decrease the excretion rate of Choline salicylate which could result in a higher serum level. |
| Chondroitin sulfate | Arsenic trioxide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. |
| Chromic chloride | Arsenic trioxide may decrease the excretion rate of Chromic chloride which could result in a higher serum level. |
| Chromic nitrate | Arsenic trioxide may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. |
| Chromium | Arsenic trioxide may decrease the excretion rate of Chromium which could result in a higher serum level. |
| Chromium gluconate | Arsenic trioxide may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. |
| Chromium nicotinate | Arsenic trioxide may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. |
| Chromous sulfate | Arsenic trioxide may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ciclesonide. |
| Cidofovir | Cidofovir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cilazapril | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cilazapril. |
| Cilostazol | The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Arsenic trioxide. |
| Cimetidine | Cimetidine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Cinchocaine. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Arsenic trioxide. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Arsenic trioxide. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Arsenic trioxide. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Cisapride is combined with Arsenic trioxide. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Arsenic trioxide. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Citalopram is combined with Arsenic trioxide. |
| Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Arsenic trioxide. |
| Clarithromycin | The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Arsenic trioxide. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Clemastine is combined with Arsenic trioxide. |
| Clevidipine | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clevidipine. |
| Clobazam | The serum concentration of Clobazam can be increased when it is combined with Arsenic trioxide. |
| Clobetasol propionate | The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Arsenic trioxide. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Arsenic trioxide. |
| Clofazimine | The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Arsenic trioxide. |
| Clomifene | The serum concentration of Clomifene can be increased when it is combined with Arsenic trioxide. |
| Clomipramine | The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Arsenic trioxide. |
| Clonazepam | Clonazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Clonidine | The risk or severity of adverse effects can be increased when Clonidine is combined with Arsenic trioxide. |
| Clopidogrel | The risk or severity of bleeding can be increased when Clopidogrel is combined with Arsenic trioxide. |
| Clorazepic acid | Clorazepic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Clostridium tetani | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Arsenic trioxide. |
| Clove oil | Arsenic trioxide may decrease the excretion rate of Clove oil which could result in a higher serum level. |
| Clozapine | The risk or severity of neutropenia can be increased when Arsenic trioxide is combined with Clozapine. |
| Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Arsenic trioxide. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Cocaine. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Arsenic trioxide. |
| Colistimethate | Colistimethate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Conivaptan | Conivaptan may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Conjugated estrogens | Conjugated estrogens may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Copanlisib | The serum concentration of Copanlisib can be increased when it is combined with Arsenic trioxide. |
| Corifollitropin alfa | Arsenic trioxide may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. |
| Corticotropin | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Arsenic trioxide. |
| Crizotinib | The serum concentration of Crizotinib can be increased when it is combined with Arsenic trioxide. |
| Cryptenamine | Arsenic trioxide may increase the hypotensive activities of Cryptenamine. |
| Cyanocobalamin | The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Arsenic trioxide. |
| Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Arsenic trioxide. |
| Cyclopenthiazide | Cyclopenthiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Arsenic trioxide. |
| Cyclosporine | Arsenic trioxide may increase the immunosuppressive activities of Cyclosporine. |
| Cyclothiazide | Cyclothiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Arsenic trioxide. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Arsenic trioxide. |
| Dabigatran | The risk or severity of bleeding can be increased when Dabigatran is combined with Arsenic trioxide. |
| Dabigatran etexilate | The serum concentration of Dabigatran etexilate can be increased when it is combined with Arsenic trioxide. |
| Dabrafenib | The serum concentration of Dabrafenib can be increased when it is combined with Arsenic trioxide. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Arsenic trioxide. |
| Dacomitinib | The serum concentration of Dacomitinib can be increased when it is combined with Arsenic trioxide. |
| Dactinomycin | The serum concentration of Dactinomycin can be increased when it is combined with Arsenic trioxide. |
| Dalfampridine | Arsenic trioxide may decrease the excretion rate of Dalfampridine which could result in a higher serum level. |
| Dalteparin | The risk or severity of bleeding can be increased when Dalteparin is combined with Arsenic trioxide. |
| Danaparoid | The risk or severity of bleeding can be increased when Danaparoid is combined with Arsenic trioxide. |
| Dapagliflozin | The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Arsenic trioxide. |
| Daptomycin | The serum concentration of Daptomycin can be increased when it is combined with Arsenic trioxide. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Arsenic trioxide. |
| Darolutamide | The serum concentration of Darolutamide can be increased when it is combined with Arsenic trioxide. |
| Darunavir | The serum concentration of Darunavir can be increased when it is combined with Arsenic trioxide. |
| Dasabuvir | The serum concentration of Dasabuvir can be increased when it is combined with Arsenic trioxide. |
| Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Arsenic trioxide. |
| Dasiglucagon | Arsenic trioxide may increase the hypotensive activities of Dasiglucagon. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Arsenic trioxide. |
| Debrisoquine | Arsenic trioxide may increase the hypotensive activities of Debrisoquine. |
| Decitabine | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Decitabine. |
| Deferiprone | Arsenic trioxide may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
| Defibrotide | The risk or severity of bleeding can be increased when Defibrotide is combined with Arsenic trioxide. |
| Deflazacort | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Deflazacort. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Arsenic trioxide. |
| Delafloxacin | The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Arsenic trioxide. |
| Delamanid | Arsenic trioxide may increase the QTc-prolonging activities of Delamanid. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Arsenic trioxide. |
| Deserpidine | Arsenic trioxide may increase the hypotensive activities of Deserpidine. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Arsenic trioxide. |
| Desipramine | The risk or severity of QTc prolongation can be increased when Desipramine is combined with Arsenic trioxide. |
| Desirudin | The risk or severity of bleeding can be increased when Desirudin is combined with Arsenic trioxide. |
| Deslanoside | Deslanoside may decrease the cardiotoxic activities of Arsenic trioxide. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Arsenic trioxide. |
| Desmopressin | Desmopressin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Arsenic trioxide. |
| Desvenlafaxine | Arsenic trioxide may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Deucravacitinib. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Deutetrabenazine. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dexamethasone. |
| Dexbrompheniramine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Arsenic trioxide. |
| Dexchlorpheniramine maleate | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Arsenic trioxide. |
| Dexibuprofen | Dexibuprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Dexketoprofen | Dexketoprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Arsenic trioxide. |
| Dexpanthenol | Arsenic trioxide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Arsenic trioxide. |
| Dextran | Arsenic trioxide may decrease the excretion rate of Dextran which could result in a higher serum level. |
| Diatrizoate | Diatrizoate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Diazepam | Diazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Diazoxide | The risk or severity of adverse effects can be increased when Diazoxide is combined with Arsenic trioxide. |
| Dichlorobenzyl alcohol | Arsenic trioxide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. |
| Diclofenac | Diclofenac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Diclofenamide | Diclofenamide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Dicoumarol | The risk or severity of bleeding can be increased when Dicoumarol is combined with Arsenic trioxide. |
| Dicyclomine | Dicyclomine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Didanosine | Didanosine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Dienogest | Arsenic trioxide may decrease the excretion rate of Dienogest which could result in a higher serum level. |
| Diflunisal | Diflunisal may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Difluocortolone | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Difluocortolone. |
| Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with Arsenic trioxide. |
| Digoxin | Arsenic trioxide may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Dihydralazine | Arsenic trioxide may increase the hypotensive activities of Dihydralazine. |
| Dihydrostreptomycin | Dihydrostreptomycin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Arsenic trioxide. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Arsenic trioxide. |
| Dimercaprol | Arsenic trioxide may decrease the excretion rate of Dimercaprol which could result in a higher serum level. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dimethyl fumarate. |
| Dimethyl sulfoxide | Dimethyl sulfoxide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dinutuximab. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Diphenhydramine. |
| Dipyridamole | The risk or severity of adverse effects can be increased when Dipyridamole is combined with Arsenic trioxide. |
| Diroximel fumarate | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Diroximel fumarate. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Arsenic trioxide. |
| Disulfiram | The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Arsenic trioxide. |
| DL-Methylephedrine | Arsenic trioxide may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. |
| Dobutamine | Dobutamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Docetaxel | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Docetaxel. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Arsenic trioxide. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Arsenic trioxide. |
| Dolutegravir | The serum concentration of Dolutegravir can be increased when it is combined with Arsenic trioxide. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Domperidone. |
| Dopamine | Dopamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Fluconazole | The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Arsenic trioxide. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Arsenic trioxide. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Arsenic trioxide. |
| Fludeoxyglucose (18F) | Arsenic trioxide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Arsenic trioxide. |
| Fluindione | The risk or severity of bleeding can be increased when Fluindione is combined with Arsenic trioxide. |
| Flumazenil | Arsenic trioxide may decrease the excretion rate of Flumazenil which could result in a higher serum level. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Arsenic trioxide. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Arsenic trioxide. |
| Fluocinonide | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Arsenic trioxide. |
| Fluocortolone | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluocortolone. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Arsenic trioxide. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Arsenic trioxide. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Arsenic trioxide. |
| Flupentixol | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Flupentixol. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluprednisolone. |
| Flurazepam | Flurazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Flurbiprofen | Flurbiprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Arsenic trioxide. |
| Flutamide | Flutamide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Fluticasone | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluticasone. |
| Fluticasone furoate | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluticasone furoate. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Arsenic trioxide. |
| Fluvoxamine | Fluvoxamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Folic acid | Folic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Fomepizole | Arsenic trioxide may decrease the excretion rate of Fomepizole which could result in a higher serum level. |
| Fondaparinux | Fondaparinux may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Formestane | Arsenic trioxide may decrease the excretion rate of Formestane which could result in a higher serum level. |
| Formoterol | The risk or severity of QTc prolongation can be increased when Formoterol is combined with Arsenic trioxide. |
| Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Arsenic trioxide. |
| Fosfomycin | Fosfomycin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Fosinopril | The risk or severity of adverse effects can be increased when Fosinopril is combined with Arsenic trioxide. |
| Fostamatinib | The risk or severity of hypotension can be increased when Fostamatinib is combined with Arsenic trioxide. |
| Fostemsavir | The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Arsenic trioxide. |
| Framycetin | Framycetin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Furosemide | Furosemide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Futibatinib | The serum concentration of Futibatinib can be increased when it is combined with Arsenic trioxide. |
| Gabapentin enacarbil | Arsenic trioxide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Arsenic trioxide. |
| Gadodiamide | Gadodiamide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Gadofosveset trisodium | Arsenic trioxide may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. |
| Gadopentetic acid | Gadopentetic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Gadoteric acid | Arsenic trioxide may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. |
| Gadoteridol | Gadoteridol may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Galantamine | The risk or severity of QTc prolongation can be increased when Galantamine is combined with Arsenic trioxide. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Gallium nitrate. |
| Ganciclovir | Ganciclovir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Arsenic trioxide. |
| Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Arsenic trioxide. |
| Gemfibrozil | Arsenic trioxide may decrease the excretion rate of Gemfibrozil which could result in a higher serum level. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Arsenic trioxide. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Arsenic trioxide. |
| Gentamicin | Arsenic trioxide may decrease the excretion rate of Gentamicin which could result in a higher serum level. |
| Gilteritinib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Arsenic trioxide. |
| Gimeracil | Arsenic trioxide may decrease the excretion rate of Gimeracil which could result in a higher serum level. |
| Givosiran | Givosiran may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Glasdegib. |
| Glatiramer | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Glatiramer. |
| Glecaprevir | The serum concentration of Glecaprevir can be increased when it is combined with Arsenic trioxide. |
| Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Arsenic trioxide. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Arsenic trioxide. |
| Glipizide | The therapeutic efficacy of Glipizide can be decreased when used in combination with Arsenic trioxide. |
| Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Arsenic trioxide. |
| Glyburide | The therapeutic efficacy of Glyburide can be decreased when used in combination with Arsenic trioxide. |
| Glycerol phenylbutyrate | Arsenic trioxide may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. |
| Glymidine | The therapeutic efficacy of Glymidine can be decreased when used in combination with Arsenic trioxide. |
| Golimumab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Golimumab. |
| Golodirsen | Arsenic trioxide may decrease the excretion rate of Golodirsen which could result in a higher serum level. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Arsenic trioxide. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Arsenic trioxide. |
| Grazoprevir | The serum concentration of Grazoprevir can be increased when it is combined with Arsenic trioxide. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Arsenic trioxide. |
| Guanabenz | Arsenic trioxide may increase the hypotensive activities of Guanabenz. |
| Guanadrel | Arsenic trioxide may increase the hypotensive activities of Guanadrel. |
| Guanethidine | Arsenic trioxide may decrease the excretion rate of Guanethidine which could result in a higher serum level. |
| Guanfacine | The risk or severity of adverse effects can be increased when Guanfacine is combined with Arsenic trioxide. |
| Guanoxan | Arsenic trioxide may increase the hypotensive activities of Guanoxan. |
| Guselkumab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Guselkumab. |
| Haemophilus influenzae | The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Arsenic trioxide. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Halofantrine. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Haloperidol. |
| Halothane | The risk or severity of adverse effects can be increased when Halothane is combined with Arsenic trioxide. |
| Heparin | The risk or severity of bleeding can be increased when Heparin is combined with Arsenic trioxide. |
| Hepatitis A Vaccine | The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Arsenic trioxide. |
| Hepatitis B Vaccine (Recombinant) | The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Arsenic trioxide. |
| Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Arsenic trioxide. |
| Human adenovirus | The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Arsenic trioxide. |
| Hydralazine | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydralazine. |
| Hydrochlorothiazide | The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Arsenic trioxide. |
| Hydrocortisone acetate | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydrocortisone acetate. |
| Hydrocortisone butyrate | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydrocortisone butyrate. |
| Hydrocortisone succinate | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydrocortisone succinate. |
| Hydroflumethiazide | Hydroflumethiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Hydromorphone | Hydromorphone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Hydroxocobalamin | Hydroxocobalamin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydroxychloroquine. |
| Hydroxyethyl Starch | Arsenic trioxide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. |
| Lapatinib | The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Arsenic trioxide. |
| Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Arsenic trioxide. |
| Lasmiditan | The serum concentration of Lasmiditan can be increased when it is combined with Arsenic trioxide. |
| Latamoxef | Latamoxef may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Arsenic trioxide. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Arsenic trioxide. |
| Leflunomide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Leflunomide. |
| Lemborexant | The serum concentration of Lemborexant can be increased when it is combined with Arsenic trioxide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Arsenic trioxide. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Arsenic trioxide. |
| Lepirudin | The risk or severity of bleeding can be increased when Lepirudin is combined with Arsenic trioxide. |
| Lercanidipine | The risk or severity of adverse effects can be increased when Lercanidipine is combined with Arsenic trioxide. |
| Lesinurad | Arsenic trioxide may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide. |
| Levacetylmethadol | The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Arsenic trioxide. |
| Levamlodipine | Arsenic trioxide may increase the hypotensive activities of Levamlodipine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Levobupivacaine. |
| Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Arsenic trioxide. |
| Levocarnitine | Levocarnitine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Levocetirizine | The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Arsenic trioxide. |
| Levodopa | The risk or severity of hypotension and orthostatic hypotension can be increased when Arsenic trioxide is combined with Levodopa. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Arsenic trioxide. |
| Levomenthol | The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Arsenic trioxide. |
| Levomilnacipran | Arsenic trioxide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. |
| Levosalbutamol | Arsenic trioxide may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Arsenic trioxide. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Lidocaine. |
| Lidoflazine | The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Arsenic trioxide. |
| Linagliptin | The therapeutic efficacy of Linagliptin can be decreased when used in combination with Arsenic trioxide. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Arsenic trioxide. |
| Liothyronine | Liothyronine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Lipegfilgrastim | Arsenic trioxide may increase the myelosuppressive activities of Lipegfilgrastim. |
| Liraglutide | The therapeutic efficacy of Liraglutide can be decreased when used in combination with Arsenic trioxide. |
| Lisinopril | The risk or severity of adverse effects can be increased when Lisinopril is combined with Arsenic trioxide. |
| Lithium carbonate | Arsenic trioxide may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Lithium citrate | Lithium citrate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Lixisenatide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Arsenic trioxide. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Arsenic trioxide. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Arsenic trioxide. |
| Lomustine | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lomustine. |
| Loncastuximab tesirine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Arsenic trioxide. |
| Loperamide | The excretion of Loperamide can be decreased when combined with Arsenic trioxide. |
| Lopinavir | The serum concentration of Arsenic trioxide can be increased when it is combined with Lopinavir. |
| Loracarbef | Loracarbef may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Lorazepam | Lorazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Lorcaserin | Arsenic trioxide may decrease the excretion rate of Lorcaserin which could result in a higher serum level. |
| Lornoxicam | Lornoxicam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Lorpiprazole | Arsenic trioxide may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. |
| Losartan | The risk or severity of QTc prolongation can be increased when Losartan is combined with Arsenic trioxide. |
| Loxoprofen | Loxoprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Lubiprostone | Lubiprostone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Lumefantrine. |
| Lumiracoxib | Lumiracoxib may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Lurasidone | The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Arsenic trioxide. |
| Lusutrombopag | The serum concentration of Lusutrombopag can be increased when it is combined with Arsenic trioxide. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Macimorelin. |
| Macitentan | Arsenic trioxide may decrease the excretion rate of Macitentan which could result in a higher serum level. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Arsenic trioxide. |
| Magnesium carbonate | Arsenic trioxide may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. |
| Magnesium chloride | Arsenic trioxide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. |
| Magnesium hydroxide | Arsenic trioxide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
| Magnesium trisilicate | Arsenic trioxide may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. |
| Mangafodipir | Arsenic trioxide may decrease the excretion rate of Mangafodipir which could result in a higher serum level. |
| Manidipine | Arsenic trioxide may increase the hypotensive activities of Manidipine. |
| Mannitol | The serum concentration of Mannitol can be increased when it is combined with Arsenic trioxide. |
| Maprotiline | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Arsenic trioxide. |
| Measles virus vaccine live attenuated | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Arsenic trioxide. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Arsenic trioxide. |
| Mecasermin | The therapeutic efficacy of Mecasermin can be decreased when used in combination with Arsenic trioxide. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Arsenic trioxide. |
| Meclofenamic acid | Meclofenamic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Medroxyprogesterone acetate | Medroxyprogesterone acetate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Mefenamic acid | Mefenamic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Mefloquine | The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Arsenic trioxide. |
| Megestrol acetate | Megestrol acetate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Meloxicam. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Arsenic trioxide. |
| Memantine | Memantine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Meningococcal vaccine | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Arsenic trioxide. |
| Meperidine | Meperidine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Mepivacaine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mepolizumab. |
| Meprednisone | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Meprednisone. |
| Mepyramine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Arsenic trioxide. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Arsenic trioxide. |
| Meropenem | Meropenem may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Mesalazine | Mesalazine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Arsenic trioxide. |
| Metamfetamine | Arsenic trioxide may decrease the excretion rate of Metamfetamine which could result in a higher serum level. |
| Metamizole | Metamizole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Metaxalone | Metaxalone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Metformin | The therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide. |
| Methadone | The risk or severity of QTc prolongation can be increased when Methadone is combined with Arsenic trioxide. |
| Methazolamide | Methazolamide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Arsenic trioxide. |
| Methohexital | Methohexital may increase the hypotensive activities of Arsenic trioxide. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Arsenic trioxide. |
| Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Arsenic trioxide. |
| Methoxsalen | Methoxsalen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Zonisamide | The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Arsenic trioxide. |
| Zofenopril | Arsenic trioxide may increase the hypotensive activities of Zofenopril. |
| Ziprasidone | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Ziprasidone. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Arsenic trioxide. |
| Zanamivir | Zanamivir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Zaleplon | Zaleplon may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Yellow fever vaccine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Arsenic trioxide. |
| Ximelagatran | The risk or severity of bleeding can be increased when Ximelagatran is combined with Arsenic trioxide. |
| Warfarin | Arsenic trioxide may decrease the excretion rate of Warfarin which could result in a higher serum level. |
| Voxilaprevir | The serum concentration of Voxilaprevir can be increased when it is combined with Arsenic trioxide. |
| Vortioxetine | Arsenic trioxide may decrease the excretion rate of Vortioxetine which could result in a higher serum level. |
| Vorinostat | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Vorinostat. |
| Voriconazole | The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Arsenic trioxide. |
| Vorapaxar | The risk or severity of bleeding can be increased when Vorapaxar is combined with Arsenic trioxide. |
| Voclosporin | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Voclosporin. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Arsenic trioxide. |
| Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Arsenic trioxide. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Arsenic trioxide. |
| Vincristine | The excretion of Vincristine can be decreased when combined with Arsenic trioxide. |
| Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Arsenic trioxide. |
| Viloxazine | Arsenic trioxide may decrease the excretion rate of Viloxazine which could result in a higher serum level. |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Arsenic trioxide. |
| Vilanterol | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Vilanterol. |
| Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Arsenic trioxide. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Arsenic trioxide. |
| Vericiguat | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Vericiguat. |
| Verapamil | The risk or severity of adverse effects can be increased when Verapamil is combined with Arsenic trioxide. |
| Venlafaxine | Venlafaxine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Venetoclax | The serum concentration of Venetoclax can be increased when it is combined with Arsenic trioxide. |
| Vemurafenib | The serum concentration of Vemurafenib can be increased when it is combined with Arsenic trioxide. |
| Velpatasvir | The serum concentration of Velpatasvir can be increased when it is combined with Arsenic trioxide. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Vedolizumab. |
| Varicella zoster vaccine | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Arsenic trioxide. |
| Varicella zoster vaccine | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Arsenic trioxide. |
| Varenicline | Arsenic trioxide may decrease the excretion rate of Varenicline which could result in a higher serum level. |
| Vardenafil | The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Arsenic trioxide. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Vandetanib. |
| Vancomycin | Arsenic trioxide may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
| Valsartan | The risk or severity of adverse effects can be increased when Valsartan is combined with Arsenic trioxide. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Arsenic trioxide. |
| Valganciclovir | Arsenic trioxide may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
| Valdecoxib | Valdecoxib may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Valbenazine | Arsenic trioxide may decrease the excretion rate of Valbenazine which could result in a higher serum level. |
| Valaciclovir | Valaciclovir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Vaborbactam | Arsenic trioxide may decrease the excretion rate of Vaborbactam which could result in a higher serum level. |
| Urokinase | The risk or severity of bleeding can be increased when Urokinase is combined with Arsenic trioxide. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Upadacitinib. |
| Umeclidinium | The serum concentration of Umeclidinium can be increased when it is combined with Arsenic trioxide. |
| Udenafil | The risk or severity of hypotension can be increased when Udenafil is combined with Arsenic trioxide. |
| Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Arsenic trioxide. |
| Typhoid Vi | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Arsenic trioxide. |
| Typhoid Vaccine Live | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Arsenic trioxide. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Arsenic trioxide. |
| Tucatinib | The serum concentration of Tucatinib can be increased when it is combined with Arsenic trioxide. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Arsenic trioxide. |
| Tropisetron | Arsenic trioxide may decrease the excretion rate of Tropisetron which could result in a higher serum level. |
| Troglitazone | The therapeutic efficacy of Troglitazone can be decreased when used in combination with Arsenic trioxide. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Arsenic trioxide. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Arsenic trioxide. |
| Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Arsenic trioxide. |
| Trimetrexate | Trimetrexate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Trimethoprim | Trimethoprim may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Trimethaphan | Arsenic trioxide may increase the hypotensive activities of Trimethaphan. |
| Trimethadione | The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Arsenic trioxide. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Arsenic trioxide. |
| Trilostane | The risk or severity of adverse effects can be increased when Trilostane is combined with Arsenic trioxide. |
| Trilaciclib | The serum concentration of Trilaciclib can be increased when it is combined with Arsenic trioxide. |
| Triflusal | The risk or severity of bleeding can be increased when Triflusal is combined with Arsenic trioxide. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Arsenic trioxide. |
| Triethylenetetramine | Arsenic trioxide may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. |
| Triclabendazole | The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Arsenic trioxide. |
| Trichlormethiazide | Trichlormethiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Triazolam | Triazolam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Triamterene | Triamterene may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Arsenic trioxide. |
| Tretinoin | The risk or severity of adverse effects can be increased when Tretinoin is combined with Arsenic trioxide. |
| Treprostinil | The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Arsenic trioxide. |
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Arsenic trioxide. |
| Trastuzumab emtansine | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Arsenic trioxide. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Arsenic trioxide. |
| Tranylcypromine | Tranylcypromine may increase the orthostatic hypotensive activities of Arsenic trioxide. |
| Trandolapril | The risk or severity of adverse effects can be increased when Trandolapril is combined with Arsenic trioxide. |
| Trametinib | Arsenic trioxide may decrease the excretion rate of Trametinib which could result in a higher serum level. |
| Tramadol | Tramadol may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Trabectedin | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Trabectedin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Arsenic trioxide. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Toremifene is combined with Arsenic trioxide. |
| Torasemide | Torasemide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Arsenic trioxide. |
| Topiramate | Topiramate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Arsenic trioxide. |
| Tolterodine | The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Arsenic trioxide. |
| Tolmetin | Tolmetin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Tolfenamic acid | Tolfenamic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. |
| Tolcapone | The risk or severity of adverse effects can be increased when Tolcapone is combined with Arsenic trioxide. |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Arsenic trioxide. |
| Tolazoline | The risk or severity of adverse effects can be increased when Tolazoline is combined with Arsenic trioxide. |
| Tolazamide | The therapeutic efficacy of Tolazamide can be decreased when used in combination with Arsenic trioxide. |
| Tofacitinib | Arsenic trioxide may increase the immunosuppressive activities of Tofacitinib. |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned
Pregnancy
ATO is teratogenic, genotoxic, and carcinogenic and passes through the placenta. Fetal exposure seems to be associated with bad pregnancy outcomes (preterm delivery, decreased birth weight, and fetal loss) and with lung diseases in young adults. No clinical trial is obviously possible, and the only data available are environmental exposure or animal studies.
Lactation
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence; the manufacturer recommends an abstinence period of 1 week after the last dose. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk
What special precautions should I follow?
Before receiving an arsenic trioxide injection,
- tell your doctor and pharmacist if you are allergic to arsenic trioxide, any other medications, or any of the ingredients in arsenic trioxide injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had liver or kidney disease.
- tell your doctor if you are pregnant, plan to become pregnant, or if you plan to father a child. If you are female, you will need to take a pregnancy test before starting treatment and use birth control to prevent pregnancy during your treatment and for at least 6 months after your final dose. If you are male, you and your female partner should use effective birth control while you are receiving arsenic trioxide injection and for 3 months after the final dose. If you or your partner becomes pregnant while using this medication, call your doctor. Talk to your doctor about using birth control to prevent pregnancy during your treatment with arsenic trioxide. Arsenic trioxide may harm the fetus.
- tell your doctor if you are breastfeeding. Your doctor will probably tell you not to breastfeed during your treatment and for 2 weeks after your final dose.
- you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving arsenic trioxide.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving arsenic trioxide.
When to contact your doctor or health care provider:
Contact your healthcare provider immediately, day or night, if you should experience any of the following symptoms:
- Fever of 100.4° F (38° C) or higher, chills (possible signs of infection)
- Difficulty breathing or shortness of breath
- Sudden weight gain
- Nausea (interferes with the ability to eat and is unrelieved with prescribed medication)
- Vomiting (vomiting more than 4-5 times in a 24-hour period)
- Rapid heartbeat (recurrent or persistent – does not go away)
- Diarrhea (4-6 episodes in a 24-hour period)
- Unusual bleeding or bruising
- Black or tarry stools, or blood in your stools
- Extreme fatigue (unable to carry on self-care activities)
Always inform your healthcare provider if you experience any unusual symptoms.
Precautions
- Before starting arsenic trioxide treatment, make sure you tell your doctor about any other medications you are taking (including prescriptions, over-the-counter, vitamins, herbal remedies, etc.).
- Avoid seafood and homeopathic remedies as these may contain arsenic.
- Do not receive any kind of immunization or vaccination without your doctor’s approval while taking arsenic trioxide.
- Inform your healthcare professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category D (arsenic trioxide may be hazardous to the fetus. Women who are pregnant or become pregnant must be advised of the potential hazard to the fetus).
- For both men and women: Do not conceive a child (get pregnant) while taking arsenic trioxide. Barrier methods of contraception, such as condoms, are recommended. Discuss with your doctor when you may safely become pregnant or conceive a child after therapy.
- Do not breastfeed while taking arsenic trioxide.
- Decreased sensation, numbness, and tingling in fingers and toes may become progressively worse with repeated doses of arsenic trioxide. It is important to report this to your doctor.
Self-Care Tips
- Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise.
- You may be at risk of infection so try to avoid crowds or people with colds, and report fever or any other signs of infection immediately to your healthcare provider.
- Wash your hands often.
- Tell dentists, surgeons, and other doctors you use Arsenic Trioxide.
- To help treat/prevent mouth sores, use a soft toothbrush, and rinse three times a day with 1/2 to 1 teaspoon of baking soda and/or 1/2 to 1 teaspoon of salt mixed with 8 ounces of water.
- Use an electric razor and a soft toothbrush to minimize bleeding.
- Avoid contact sports or activities that could cause injury.
- To reduce nausea, take anti-nausea medications as prescribed by your doctor, and eat small, frequent meals.
- Avoid sun exposure. Wear SPF 30 (or higher) sunblock and protective clothing.
- In general, drinking alcoholic beverages should be kept to a minimum or avoided completely. You should discuss this with your doctor.
- Get plenty of rest.
- Maintain good nutrition.
- If you experience symptoms or side effects, be sure to discuss them with your healthcare team. They can prescribe medications and/or offer other suggestions that are effective in managing such problems.
- Use birth control that you trust to avoid pregnancy while taking Arsenic Trioxide.
- If you are male, use birth control to protect a female you are having sex with from becoming pregnant while you are using Arsenic Trioxide and for some time after stopping. Talk with your doctor about how long to use birth control after stopping Arsenic Trioxide.
- For flu-like symptoms, keep warm with blankets and drink plenty of liquids. There are medications that can help reduce the discomfort caused by chills.
- Acetaminophen or ibuprofen may help relieve discomfort from fever, headache, and/or generalized aches and pains. However, be sure to talk with your doctor before taking it.
References
